Table II.
Association between the expression of CXCR1/2 and clinicopathological factors of gastric carcinoma.
| Expression
|
||||
|---|---|---|---|---|
| Characteristics | Negative (n=1) | Weak (n=45) | Strong (n=23) | P-value |
| Male:female | 0:1 | 37:8 | 18:5 | 0.452 |
| Age (years), mean ± SD | 53.0±0 | 52.3±20.0 | 56.0±27.3 | 0.501 |
| Cancer cell differentiation | 0.357 | |||
| Good | 0 | 5 | 2 | |
| Moderate | 0 | 17 | 7 | |
| Poor | 1 | 23 | 14 | |
| T stage | <0.001 | |||
| T1 | 0 | 3 | 0 | |
| T2 | 0 | 13 | 0 | |
| T3 | 1 | 20 | 15 | |
| T4 | 0 | 9 | 8 | |
| N stage | <0.001 | |||
| N0 | 1 | 20 | 1 | |
| N1 | 0 | 17 | 4 | |
| N2 | 0 | 7 | 5 | |
| N3 | 0 | 1 | 13 | |
| Overall stage | <0.001 | |||
| I | 0 | 8 | 0 | |
| II | 1 | 30 | 2 | |
| III | 0 | 6 | 21 | |
| IV | 0 | 1 | 0 | |
CXCR1/2, C-X-C chemokine receptor types 1/2.